Border to Coast Pensions Partnership Ltd Raises Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Border to Coast Pensions Partnership Ltd lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 8.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 83,608 shares of the medical research company's stock after acquiring an additional 6,847 shares during the period. Border to Coast Pensions Partnership Ltd's holdings in Thermo Fisher Scientific were worth $51,566,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. James Hambro & Partners LLP boosted its holdings in Thermo Fisher Scientific by 5.7% in the third quarter. James Hambro & Partners LLP now owns 209,453 shares of the medical research company's stock worth $129,524,000 after purchasing an additional 11,276 shares during the last quarter. Castleview Partners LLC lifted its holdings in Thermo Fisher Scientific by 2.2% in the third quarter. Castleview Partners LLC now owns 1,656 shares of the medical research company's stock valued at $1,024,000 after acquiring an additional 36 shares during the period. MBE Wealth Management LLC grew its stake in shares of Thermo Fisher Scientific by 2.6% during the 3rd quarter. MBE Wealth Management LLC now owns 1,278 shares of the medical research company's stock valued at $791,000 after purchasing an additional 32 shares during the period. Bellecapital International Ltd. increased its position in shares of Thermo Fisher Scientific by 7.4% during the 3rd quarter. Bellecapital International Ltd. now owns 10,168 shares of the medical research company's stock valued at $6,290,000 after purchasing an additional 703 shares during the last quarter. Finally, Arlington Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 18.8% in the third quarter. Arlington Partners LLC now owns 6,651 shares of the medical research company's stock worth $4,114,000 after buying an additional 1,053 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company's stock, valued at approximately $76,420,473.36. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $76,420,473.36. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 6,300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $602.09, for a total transaction of $3,793,167.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company's stock, valued at $74,548,375.44. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,084 shares of company stock valued at $14,094,292. 0.34% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on TMO. Evercore ISI lifted their price target on shares of Thermo Fisher Scientific from $605.00 to $630.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 1st. Stephens assumed coverage on Thermo Fisher Scientific in a report on Tuesday, October 1st. They set an "overweight" rating and a $680.00 price target for the company. Royal Bank of Canada reaffirmed an "outperform" rating and set a $767.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, September 20th. JPMorgan Chase & Co. raised their target price on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an "overweight" rating in a research note on Friday, September 20th. Finally, Robert W. Baird increased their price objective on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an "outperform" rating in a research note on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $656.16.

Thermo Fisher Scientific Price Performance

TMO stock traded down $6.36 during trading on Monday, hitting $595.35. 914,622 shares of the company's stock traded hands, compared to its average volume of 1,464,182. The business has a fifty day simple moving average of $607.99 and a 200 day simple moving average of $584.23. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72. The stock has a market capitalization of $227.42 billion, a price-to-earnings ratio of 37.33, a P/E/G ratio of 3.85 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, beating the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The company had revenue of $10.54 billion for the quarter, compared to analyst estimates of $10.50 billion. During the same quarter in the prior year, the firm posted $5.15 EPS. Thermo Fisher Scientific's quarterly revenue was down 1.4% compared to the same quarter last year. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.